<DOC>
	<DOC>NCT00429377</DOC>
	<brief_summary>This study consists of a 28-week placebo-controlled double-blind inter-group efficacy study in steroid refractory Lupus Nephritis patients.</brief_summary>
	<brief_title>Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Steroid refractory lupus nephritis more than 10mg of steroid failed to control disease activity patients who failed to reduce the amount of steroid patients who couldn’t increase the amount of steroid due to side effects Patients who started the immunosuppressant therapy or increased the amount of immunosuppressant within 12 weeks prior to test drug administration Patients who received cyclophosphamide puls within 24 weeks prior to test drug administration CNS( Central Nerve System) Lupus patients hepatic failure patients Serum creatinine ≧1.5mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>FK506</keyword>
	<keyword>lupus nephritis</keyword>
</DOC>